San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, DTx Pharma is raising $12,500,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Arthur Suckow played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DTx Pharma

DTx Pharma is developing technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across most therapeutic areas. DTx has developed proprietary technology based on lipidation, the direct conjugation of long chain fatty acids to siRNA, that enables delivery of siRNA therapeutics across multiple cell types.  This technology enables oligonucleotide therapeutics to compete with small molecules and other biologics across most indications and additionally, enables access to drug targets and indications that small molecules and biologics could never be able to modulate.

To learn more about DTx Pharma, visit http://dtxpharma.com/

Contact:
Arthur Suckow, Chief Executive Officer
(858) 242-1504
https://www.linkedin.com/in/arthur-suckow-ph-d-a460a84/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved